ReviewFrontiers in bioengineering and biotechnology2022
Phase-change materials-based platforms for biomedicine.
Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Dual-Stimuli Responsive Nanoplatform via Atomic Layer Deposition of Gold on CoFeInternational journal of nanomedicine · 2026Article
- Carbon-Enhanced Hydrated Salt Phase Change Materials for Thermal Management Applications.Nanomaterials (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, phase-change materials (PCMs) have gathered enormous attention in diverse fields of medicine, particularly in bioimaging, therapeutic delivery, and tissue engineering. Due to the excellent physicochemical characteristics and morphological characteristics of PCMs, several developments have been demonstrated in the construction of diverse PCMs-based architectures toward providing new burgeoning opportunities in developing innovative technologies and improving the therapeutic benefits of the existing formulations. However, the fabrication of PCM-based materials into colloidally stable particles remains challenging due to their natural hydrophobicity and high crystallinity. This review systematically emphasizes various PCMs-based platforms, such as traditional PCMs (liposomes) and their nanoarchitectured composites, including PCMs as core, shell, and gatekeeper, highlighting the pros and cons of these architectures for delivering bioactives, imaging anatomical features, and engineering tissues. Finally, we summarize the article with an exciting outlook, discussing the current challenges and future prospects for PCM-based platforms as biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.